Expert consensus on prescription review rules of anticoagulants / 中国药房

ABSTRACT

@#OBJECTIVE To further standardize the clinical application of anticoagulants and provide reference for improving the efficiency of prescription review of anticoagulants in medical institutions. METHODS Initiated by the Pharmaceutical Administration Committee of Chongqing Hospital Association and led by the Second Affiliated Hospital of Chongqing Medical University， in collaboration with experts in relevant fields from multiple provinces across the country， the prescription review rules， warning levels， and intervention measures for 12 kinds of common anticoagulants were established based on drug instructions. Regarding clinical drug use that was not covered by the basic review rules， based on reference to existing guidelines and expert consensus， 42 experts from 22 hospitals in 8 provinces across the country were consulted by letter to form a consensus. RESULTS & CONCLUSIONS The basic prescription review rules of 12 kinds of anticoagulants， including unfractionated heparin， enoxaparin sodium， nadroparin calcium， dalteparin sodium， fondaparinux sodium， bivalirudin， argatroban， warfarin， dabigatran etexilate， rivaroxaban， apixaban and edoxaban， had been established according to drug instruction， as well as warning levels beyond the basic review rules and corresponding intervention measures. After two rounds of expert consultation， 17 recommendations for prescription review were formed regarding some clinical drug use that were not covered by the basic prescription review rules. With the progress of clinical research， this consensus will be further updated and adjusted； in addition， as this consensus does not cover all situations where anticoagulants are used in clinical practice， prescription reviewer must conduct personalized evaluations based on the specific situation of the patient.